Projecting the Impact of Immunotherapy in Advanced Ovarian Cancer
Published: Friday, Aug 30, 2019
Rebecca C. Arend, MD
Unlike PARP inhibitors, which are showing extensive utility in a broader group of patients with advanced ovarian cancer, the impact of immunotherapy will likely be seen on a smaller scale. The onus, explained Rebecca C. Arend, MD, will lie in defining the patient subset in which this approach will provide the most benefit.
... to read the full story